METTL3 and hematologic disorder: STM2457, originally developed as a selective METTL3 inhibitor for hematologic malignancies, demonstrates several pharmacological properties that favor potential clinical development, including its small molecule structure, nanomolar potency, ability to cross the blood brain barrier, and capacity to reduce m6A levels in vivo37.